"Hypertension, Pulmonary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Descriptor ID |
D006976
|
| MeSH Number(s) |
C08.381.423
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hypertension, Pulmonary".
Below are MeSH descriptors whose meaning is more specific than "Hypertension, Pulmonary".
This graph shows the total number of publications written about "Hypertension, Pulmonary" by people in this website by year, and whether "Hypertension, Pulmonary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 3 | 0 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 0 | 4 |
| 2005 | 8 | 2 | 10 |
| 2006 | 4 | 0 | 4 |
| 2007 | 7 | 0 | 7 |
| 2008 | 4 | 0 | 4 |
| 2009 | 12 | 3 | 15 |
| 2010 | 8 | 0 | 8 |
| 2011 | 10 | 4 | 14 |
| 2012 | 13 | 2 | 15 |
| 2013 | 12 | 2 | 14 |
| 2014 | 17 | 1 | 18 |
| 2015 | 14 | 4 | 18 |
| 2016 | 15 | 1 | 16 |
| 2017 | 15 | 1 | 16 |
| 2018 | 17 | 3 | 20 |
| 2019 | 5 | 0 | 5 |
| 2020 | 8 | 2 | 10 |
| 2021 | 12 | 2 | 14 |
| 2022 | 19 | 0 | 19 |
| 2023 | 14 | 0 | 14 |
| 2024 | 9 | 3 | 12 |
| 2025 | 6 | 0 | 6 |
| 2026 | 6 | 2 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypertension, Pulmonary" by people in Profiles.
-
Pulmonary hypertension in anti-synthetase syndrome: prevalence, comparative risk across autoimmune diseases and impact on survival. Rheumatology (Oxford). 2026 Oct 01; 65(10).
-
Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms. Int J Hematol. 2026 Nov; 124(5):640-648.
-
Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension. JCI Insight. 2026 05 22; 11(10).
-
Dynamin 2 Regulates Mitochondrial Mitotic Fission in Pulmonary Hypertension. Circ Res. 2026 May 22; 138(11):e327028.
-
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 May; 67(6):1335-1342.
-
3D echo derived right ventricular principal surface strain in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2026 03 01; 330(3):H729-H736.
-
Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of Heart Failure and Pulmonary Hypertension: A Scientific Statement From the American Heart Association. Circ Heart Fail. 2026 Feb; 19(2):e000088.
-
Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes. Am J Respir Crit Care Med. 2026 01 01; 212(1):117-128.
-
Macrophage plasticity and glucose metabolism: the role of immunometabolism in pulmonary arterial hypertension. Clin Sci (Lond). 2025 10 01; 138(19).
-
Pathogenic Concepts in Pulmonary Arterial Hypertension Revisited: A Multigenerational Perspective. Am J Respir Cell Mol Biol. 2025 08; 73(2):200-209.